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ABSTRACT
Benzene is a common environmental toxin and its metabolite, 1-4-Benzoquinone 
(BQ) causes hematopoietic cancers like myelodysplastic syndrome (MDS) and acute 
myeloid leukemia (AML). BQ has not been comprehensively assessed for its impact on 
genome maintenance, limiting our understanding of the true health risks associated 
with benzene exposure and our ability to identify people with increased sensitivity 
to this genotoxin. Here we analyze the impact BQ exposure has on wild type and 
DNA repair-defective mouse embryonic stem (ES) cells and wild type human cells. 
We find that double strand break (DSB) repair and replication fork maintenance 
pathways including homologous recombination (HR) and Fanconi anemia (FA) 
suppress BQ toxicity. BQ-induced damage efficiently stalls replication forks, yet poorly 
induces ATR/DNA-PKCS responses. Furthermore, the pattern of BQ-induced γH2AX 
and 53BP1foci is consistent with the formation of poly(ADP-ribose) polymerase 1 
(PARP1)-stabilized regressed replication forks. At a biochemical level, BQ inhibited 
topoisomerase 1 (topo1)-mediated DNA ligation and nicking in vitro; thus providing 
mechanism for the cellular phenotype. These data are consistent with a model that 
proposes BQ interferes with type I topoisomerase’s ability to maintain replication fork 
restart and progression leading to chromosomal instability that has the potential to 
cause hematopoietic cancers like MDS and AML.
INTRODUCTION
Few occupational or environmental hazards are 
unambiguously linked to the development of myeloid 
neoplasms. This is partly due to the uncertainty between 
the time of exposure and the appearance of symptoms. 
In addition, criteria for diagnosing these diseases have 
dramatically changed over the years, in particular for 
myelodysplastic syndrome (MDS), which complicates the 
evaluation of old patient records. Nevertheless, decades 
of follow-up studies and reexamining pathology reports 
show that adults who were exposed at the work place to 
cumulative high levels, or chronic low levels of benzene 
have an increased risk of developing MDS or acute 
myeloid leukemia (AML), respectively [1–3].
Benzene is a colorless volatile liquid hydrocarbon 
found in coal tar and petroleum and is used to make numerous 
chemical products including detergents, insecticides and 
motor fuels [4, 5]. The primary benzene metabolite to cause 
genomic damage is 1,4-benzoquinone (BQ) and is believed 
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to be responsible for the myelotoxicity/myeloid neoplasms 
observed in the bone marrow of people who have been 
exposed to increased levels of benzene [4]. In addition to 
specific industry-related work places, benzene concentrations 
are also significantly higher in and around cities with a 
high coal or oil-based energy consumption, as well as in 
rural areas subject to heavy pesticide use. This raises the 
question whether environmental benzene pollution can be 
a contributing factor to MDS and AML development. In 
support of this notion is the increased incidence of childhood 
leukemia observed in Harris county, Texas (Houston area), 
which houses several petroleum and chemical industries that 
are associated with air pollutants, including benzene [6]. In 
addition, several studies report that MDS is diagnosed on 
average a decade earlier in Asian countries compared to 
Western countries [7–11]. Since the former countries use 
mostly coal to fuel their industries [12] and households, 
systemic exposure to environmental toxins such as benzene, 
could be responsible for their earlier onset of MDS.
An alternative explanation for the difference in age 
of MDS onset between Western and Asian populations is 
a difference in genetic make-up. There is no doubt that 
an individual’s machinery responsible for proper genome 
maintenance suppresses hematologic cancers [13]. This is 
particularly apparent in diseases characterized by poor DNA 
repair capacity [14, 15]. For example, patients with Fanconi 
Anemia (FA) are defective for genome maintenance and 
exhibit a high incidence of MDS and AML [16]. Moreover, 
alternative SNPs in multiple DNA repair genes were 
found to associate with hematotoxicity in adults routinely 
exposed to benzene [17]. The difference in childhood 
leukemia onset in specific Texas counties may also have 
an underlying genetic basis. Texas is home to a large 
Hispanic population and several studies have shown that 
Hispanic children exhibit a significantly higher incidence 
and worse outcome of acute lymphocytic leukemia (ALL) 
compared to non-Hispanic children. Specifically, Hispanic 
children in Texas who developed ALL overrepresented 
several polymorphisms in genes known to associate with 
cancer development when mutated [18, 19]. This same 
group of children exhibited a significantly higher risk for 
developing secondary MDS/AML after receiving etoposide 
(a topoisomerase type II inhibitor that was part of their ALL 
treatment) [20]. Thus, occupational and environmental 
exposures to benzene, as well as poor DNA damage 
response/repair can enhance the risk for the development of 
hematologic cancers like MDS and AML.
Very little is known about the mechanisms required 
to cope with benzene-induced DNA damage. This lack 
of understanding hampers a more detailed assessment of 
the risk benzene exposure poses to people and our ability 
to identify those at high risk for MDS and AML. The 
current study was initiated to increase our understanding 
of the consequences of benzene-induced DNA damage 
and the mechanisms required to repair it. We found that 
the benzene metabolite, BQ induced chromosomal breaks 
and rearrangements as well as stalled replication forks, 
which required DSB repair and the FA pathway to correct. 
Furthermore, BQ directly interfered with the ability of 
type 1 topoisomerase (topo 1) to nick DNA and relieve 
supercoiling. Topo 1 interference is consistent with the 
observations that BQ-induced damage causes replication 
fork regression that could lead to chromosomal breaks 
and rearrangements, especially if DSB repair and FA 
pathways are compromised. Thus, these data support 
the observations that benzene enhances risk of MDS and 
AML especially for those with compromised genome 
maintenance capacity.
RESULTS
Cells defective for DSB repair and replication 
fork stability are hypersensitive to BQ
We previously developed a screening system to 
identify the DNA repair pathway(s) most important for 
repairing DNA lesions induced by a given genotoxin [21]. 
This screen will generate a genotoxic profile of the toxin 
under investigation and it is based on a comprehensive set 
of mouse embryonic stem (ES) cells defective for specific 
DNA repair pathways, including those that repair base 
lesions, replication errors, double strand breaks (DSBs) 
and interstrand and intrastrand crosslinks (Table 1) [21]. 
To create a BQ genotoxic profile, we performed a dose 
response curve for each mutant cell line to determine the 
threshold BQ concentrations that reduce cell survival 
[22]. Mutant cells that are more sensitive to threshold BQ 
concentrations as compared to their parental control reveal 
a pathway important for correcting BQ-induced damage. 
Thus, this screening method takes an unbiased approach 
to discover the DNA repair pathways most important for 
correcting BQ-induced damage.
The mutant cells used for the BQ genotoxic profile 
are summarized in Table 1. The survival difference 
between mutant relative to control cells is shown at 
BQ concentrations that reduce mutant cell survival by 
90% and 99% (black and grey bars, respectively). For 
example, at a BQ dose that reduces the survival of 
Brca1-mutant cells by 90% and 99%; the mutant cells 
exhibited an 8-fold and a 17-fold increase in sensitivity 
(measured as reduced cell survival) compared to control 
cells, respectively. This observation suggests BQ induces 
DNA breaks and destabilizes replication forks since 
BRCA1 is needed to address these problems as a member 
of HR. In support, cells mutated for other DSB repair 
and replication fork maintenance genes also exhibited 
>5-fold hypersensitivity to BQ (Figure 1A). These 
include cells defective for FA (Fancb), nonhomologous 
end joining (NHEJ, Ku70) and interstrand crosslink 
repair (ICLR)/HR (Ercc1). By comparison, cells with 
a mutation in a lesion bypass gene, Trex2, caused BQ-
resistance supporting the notion that DSB repair and 
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replication fork maintenance are important for correcting 
BQ-induced lesions since Trex2-deletion is known to 
increase HR and NHEJ [23, 24]. The Brca2-mutant cells 
did not exhibit profound hypersensitivity even though 
BRCA2 is important for DSB repair and replication 
fork maintenance [25]. However, these cells produce 
wild type levels of a C-terminally truncated protein 
that is defective in RAD51 filament stability which 
causes only a minor phenotype [25–28]. Taken together, 
these data suggest that DSB repair and replication fork 
maintenance are essential for efficiently repairing BQ-
induced damage.
Others have shown that BQ inhibits type II 
topoisomerases [29], leading to the formation of 
apoptosis-inducing type I topoisomerase cleavage 
complexes [30]. We therefore hypothesized that the 
genotoxic profile of BQ could resemble that of a type 
II topoisomerase poison such as etoposide (ETO) and 
potentially that of a type 1 topoisomerase inhibitor such 
as camptothecin (CPT). Indeed, like BQ, ETO exposure 
caused hypersensitivity in cells defective in DSB repair 
and replication fork maintenance (Figure 1B). Curiously, 
Msh2-/- cells exposed to ETO show antithetical responses 
depending on dose. It is possible at the lower dose Msh2-
/- cells were resistant because MSH2 hindered replication 
fork progression while at the higher dose MSH2 were 
hypersensitive because MSH2 was needed to corrected 
damage that severely disabled replication or induced 
apoptosis. We then assessed the dose response to CPT in 
the mutant ES cell lines most sensitive to BQ and ETO 
(cells mutated for Brca1, H2ax, Ku70 and Ercc1). Cells 
defective for HR (Brca1, H2ax) and ICLR (Ercc1) were 
hypersensitive to CPT, similar to BQ and ETO. Yet the 
NHEJ-defective cells (Ku70) were mildly resistant to 
CPT, suggesting that NHEJ performs a toxic function 
when encountering CPT-induced damage, unlike the 
response to BQ- and ETO-induced lesions. Thus, DSB 
repair and replication fork maintenance appear to be 
critical for correcting lesions caused by BQ, ETO 
and CPT.
Table 1: Summary of mutant ES cells
Control cells Gene Mutations Function
AB1.1 Msh2 -/- MMR
AB2.2 Brca2 Exon 27 deletion HR
Blm 88% decrease Helicase/HR
Recql5 -/- Helicase/HR
Trex2 -/- Exonuclease/RF
FancB Exon 2 deletion ICLR/RF
B44 Xpa -/- NER
Xpc -/- NER
J1 Ku70 -/- cNHEJ
TC1 H2AX -/- DDR/HR
Brca1 BRCT deletion DDR/HR/NHEJ
IB10 Rad18 -/- Lesion bypass




Cells were used that were ablated for nucleotide excision repair (NER) (Xpa [73], Xpc [74]), mismatch repair (MMR, 
Msh2) [75], lesion bypass (Rad18) [76], the Fanconi anemia (FA) pathway (Fancb) [77], nonhomologous end joining 
(NHEJ, Ku70) [78]. Complete ablation of homologous recombination (HR) is cell lethal [79]; therefore, null cells were 
used for genes that contribute to, but are not essential for HR (H2ax [80], Rad52 [81], Rad54 [82]). Cells were used that are 
partially defective for essential proteins that include a deletion of Brca2 exon 27 [26] and deletion of Brca1 exon 11 [83]. 
Cells were used that are defective for HR regulation that include mutations in the helicases Blm [84] and Recql5 [85]. Cells 
were used that are defective for endonucleases (Mus81 [86] and Ercc1 [87]) that can be used during HR and interstrand 
crosslink repair (ICLR) and exonucleases (Trex2) [88] that can be used for lesion bypass.
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BQ causes less chromosomal damage than ETO 
and CPT
The BQ genotoxic profile predicts that cells 
defective in DSB repair and replication fork maintenance 
will exhibit extensive chromosomal damage after BQ 
exposure; therefore, we evaluated chromosome integrity 
of relevant ES cell lines using two-color fluorescence in 
situ hybridization (FISH) on metaphase spreads (MPSs). 
DAPI counterstained chromosomes were stained with 
a telomere and a pericentromere probe [31]. We scored 
isochromatid breaks, chromatid breaks, radials and EPTs 
(extra pericentromeres and telomeres) (Figure 2A) [32]. 
Chromatid breaks indicate one-ended breaks observed 
at collapsed replication forks while isochromatid breaks 
indicate failed strand exchange intermediates that break 
both chromatids. Radials suggest chromosomal structures 
that result from the fusion of multiple chromosomes, 
such as those commonly observed in cells derived from 
FA patients after exposure to DNA crosslinking agents 
[33]. EPTs are complex rearrangements that occur in HR-
defective cells that implicate multiple fusions possibly due 
to faulty replication or the imprecise joining of multiple 
DSBs [32]. Thus, two-color FISH will detect a range of 
chromosomal defects.
BQ-induced damage was compared to that of ETO 
and CPT because all three genotoxins showed similar 
results in the screening assay. We focused on those mutant 
ES cells that showed a hypersensitive phenotype in 
response to BQ (Ercc1-/-, Ku70-/-, H2ax-/-, Brca1Δ11/Δ11 and 
Figure 1: The genotoxic profile that compares the survival fraction of mutant ES cells to their parental controls at 
10% (black bar) and at 1% (grey bar) cell survival. A. Exposure to 1,4-Benzoquinone (BQ). B. Exposure to etoposide (ETO). 
C. Exposure to camptothecin (CPT).
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FancbΔex2 ES cells). Physiologically comparable doses of 
genotoxins were used that produced a survival fraction 
of ~40-70% and ~5-20% for control and mutant cells, 
respectively (Figure 2B–2E, left panels). Therefore, these 
genotoxins are being compared at comparably toxic doses. 
At these doses, BQ caused fewer chromosomal defects 
than either ETO or CPT (Figure 2B–2E, right panels, 
Supplementary Table S1A-S1D, Supplementary Table 
S2A-S2D). Yet, this difference dissipates in FancbΔex2 cells 
implicating the FA pathway as central for repairing BQ-
induced damage. FANCB is an essential member of the FA 
core complex [34] that is capable of monoubiquitinating 
FANCD2 in a minimal subcomplex [35] and its disruption 
completely destroys core complex function [36]. The FA 
pathway is important for replication fork maintenance, in 
particular protection of the nascent strand [37, 38]. These 
results suggest that BQ-mediated DNA damage has the 
potential to disrupt replication.
Figure 2: Evaluation of chromosome damage in metaphase spreads (MPS) after ES cells were exposed to BQ, ETO 
and CPT. A. Images of H2ax-/- cells exposed to 1) nothing, 2) BQ, 3) CPT and 4) ETO. Arrowheads point to chromosomal abnormalities. 
Enlarged representative examples of chromosomes include 5) normal, 6) isochromatid break (ICB), 7) chromatid break (CB), 8) radial 
and 9) extrapericentromeres and telomeres (EPT). B–E. The survival fraction (%SF) is shown on the left panel and the # of chromosomal 
defects is shown on the right panel. (B) Wild type and Ercc1-mutant IB10 cells. (C) Wild type and Ku70-mutant J1 cells. (D) Wild type and 
H2ax- and Brca1-mutated TC1 cells. (E) Wild type and Fancb-mutated AB2.2 cells. Cells were also exposed to an equivalently toxic dose 
of Mitomycin C (MMC), a crosslinking agent that is known to be very toxic to FA-defective cells. The concentration for CPT (100 nM, 
16 hours) and MMC (30 nM, 16 hours) results in ~ 10% and 90% survival for control cells and ~ 10% and <0.001% survival for FancbΔex2 
cells as previously reported [38]. Note that MMC induces a much larger level of cell death and radials relative to control cells than the other 
agents relative to control cells demonstrating that FancbΔex2 cells are particularly susceptible to MMC as compared to the other agents. The 
total number of MPS observed for each bar and statistics are shown in supplemental tables 1 and 2, respectively.
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BQ is more efficient at stalling replication forks 
than ETO and CPT
DNA fiber analysis was used to measure replication 
fork restart in response to BQ in control and FancbΔex2 cells 
since the FA pathway is important for coping with BQ-
induced DNA damage and since FA stabilizes replication 
forks [37, 38]. In this assay, BQ was compared to a positive 
control, hydroxyurea (HU). HU inhibits ribonucleotide 
reductase, which depletes nucleotides [39] to impair the 
restart of replication forks [25]. Physiologically comparable 
doses of genotoxins (1.5 hr of 10 μM BQ or 0.5 mM HU) 
were used that produced a survival fraction of ~80-90% 
in control cells (Figure 3A). This particular dose of HU 
does not cause breaks [23, 25] and has a mild effect on 
replication fork restart and origin firing in control cells 
(Figure 3B, Supplementary Tables S3 & S4). In contrast, 
BQ significantly reduced levels of restart while it increased 
levels of new origin firing (Figure 3B). In FancbΔex2 cells, 
both BQ and HU reduced restart and new origins, with BQ 
being more severe (Figure 3C). A higher BQ concentration 
did not exacerbate these observations, suggesting the lower 
dose already produced the maximal effect (Figure 3B, 3C).
BQ’s impact on replication fork restart was 
compared to that of ETO and CPT, in control and FancbΔex2 
cells. Physiologically comparable doses of genotoxin (0.5 
hr of 60 μM BQ or 1 μM ETO/CPT) were used, producing 
a survival fraction of ~40-60 % for control cells (Figure 
3D). In control cells, BQ reduced replication fork restart 
more than ETO and CPT (Figure 3E). By contrast in 
FancbΔex2 cells, all three genotoxins reduced replication 
fork restart with BQ being the most severe (Figure 3F). 
Thus, BQ blocks replication fork restart more than HU, 
ETO and CPT, which is exacerbated in FA-defective cells.
BQ is not efficient at inducing ATR/DNA-PKCS 
responses to stalled replication forks
A fork that fails to restart can be temporarily stalled or 
more severely collapsed, possibly without a replisome [40]. 
The latter is more likely to form an intermediate structure 
amenable to a chromosomal rearrangement with potential 
for disease development, yet they are indistinguishable 
at the level of fiber analysis. Therefore, iPOND was used 
to observe the severity of the defect in replication fork 
restart by observing the phosphorylation pattern of RPA 
Figure 3: Fiber analysis. A-C. ES cells were exposed to IdU for 20 minutes and then agent (BQ or HU) for 90 minutes and then CldU 
for 20 minutes. (A) Percent survival fraction (%SF) using the identical condition as the fiber analysis. (B) Fiber analysis in wild type AB2.2 
cells. (C) Fiber analysis in Fancb-mutant cells. D-E. ES cells were exposed to IdU for 30 minutes and CldU + agent for 30 minutes. (D) 
Percent survival fraction (%SF) using the identical conditions for the fiber analysis. E. Fiber analysis in wild type AB2.2 cells. F. Fiber 
analysis in Fancb-mutant cells. The total number of fibers observed for each bar and statistics are shown in supplemental tables S3 and S4, 
respectively.
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32 [32, 41]. RPA 32 associates with single strand DNA at 
replication forks [42]. ATR phosphorylates serine 33 for a 
mild response while DNA-PKCS phosphorylates serines 4 
and 8 for a severe response [43]. For ES cells, a low HU 
dose (0.5 mM, 1.5 hours) induces an ATR response while 
a high HU dose (4 mM, 5 hours) induces both an ATR and 
a DNA-PKCS response [25]. Previously we showed that 
the high HU dose produced more chromatid breaks; thus 
indicating collapsed forks with DSBs [25]. We compared 
similar physiologically toxic doses of BQ, ETO and CPT to 
that of low and high dose HU (Figure 4A). We found that 
all genotoxins caused an ATR response at the high doses 
but only ETO and HU caused this response at the low doses 
(Figure 4B, 4C). Furthermore, only high dose HU caused 
a DNA-PKCS response (Figure 4B, 4D). For confirmation, 
we also purified γH2AX since it recognizes DNA DSBs 
[44] and single strand DNA at stalled replication forks [41]. 
We found that γH2AX levels directly correlated with the 
severity of the response such that the highest levels purified 
in HU exposed cells followed by ETO, CPT and BQ. Thus, 
the purification of γH2AX correlates with dose severity 
similar to RPA 32 phosphorylation. Therefore, from the 
genotoxins tested here, BQ is efficient at inhibiting fork 
restart (fiber analysis), but not efficient at inducing an ATR/
DNA-PKCS response or a γH2AX response (iPOND).
BQ causes stalled replication forks to regress
We next observed the nature of individual stalled 
forks and DSBs induced by BQ since fibers suggest 
BQ efficiently inhibits fork restart but iPOND suggests 
minimal ATR/DNA-PKCS responses indicating that BQ-
induced stalled forks are stabilized and not subject to these 
responses. Previously, CPT was shown to induce stalled 
forks that regress and form a chicken foot (Figure 5A). 
Fork regression could stabilize stalled forks to minimize 
ATR/DNA-PKCS responses. The localization of γH2AX 
and 53BP1 foci can be used to identify regressed forks. 
Similar to γH2AX, 53BP1 associates with damaged 
DNA to form nuclear foci [45]. Nuclei without foci 
implicate little to no damage (Figure 5B, 1st row). Nuclei 
with colocalized foci (a merge of γH2AX and 53BP1) 
implicate replication-independent damage that does not 
cause chicken feet as seen after exposure to γ-radiation 
(Figure 5B, 2nd row) [46]. By contrast nuclei with 
single-protein foci (either γH2AX or 53BP1) implicate 
replication-dependent damage that cause chicken feet as 
seen after exposure to CPT (Figure 5B, 3rd and 4th rows). 
Furthermore, PARP1 stabilizes chicken feet by inhibiting 
RECQ1 helicase and the PARP1 inhibitor, olaparib (OLA) 
reduces chicken feet [47, 48] such that exposure to OLA 
will reduce the number of nuclei with single-protein foci 
and an increase of nuclei with merged foci [47, 48]. Thus, 
the analysis of γH2AX and 53BP1 foci will measure the 
presence of PARP1-stabilized chicken feet.
We evaluated γH2AX and 53BP1 foci to determine 
if BQ induced PAPR1-stabilized chicken feet. Gamma-
radiation and CPT were used as controls since both 
cause DSBs but only CPT promotes chicken feet. Cells 
were exposed to a variety of γ-radiation doses that result 
Figure 4: The purification of γH2AX and RPA at the nascent replication strand using iPOND. A. The percent survival 
fraction (%SF) using the same condition as for iPOND. B. Western blot to evaluate the protein concentrations at purified nascent replication 
strands. C-E. Graphs that depict the quantitation of 3 Western blots for (C) γH2AX, (D) RPA pS33 and (E) RPA pS4/S8. Error bars are 
shown for the average of 3 experiments.
Oncotarget46440www.impactjournals.com/oncotarget
in a survival fraction of ~97% (1Gy), ~60% (2 Gy) and 
~7% (10 Gy). A dose of genotoxin that is physiologically 
comparable to the milder γ-radiation doses was used for 
the other genotoxins (Figure 5C). In addition, a mild OLA 
dose was used that had only minimal or no impact on cell 
survival in the presence of genotoxin (Figure 5C). As 
expected, γ-radiation (with or without OLA) resulted in a 
strong majority of nuclei with colocalized foci (no chicken 
feet) while CPT resulted in a majority of nuclei with 
single-protein foci (chicken feet) and OLA reduced the 
proportion of these nuclei (implicating PARP1-stabilized 
regressed forks) (Figure 5D, Supplementary Tables S5 & 
S6). Exposure to BQ was almost identical to CPT (except 
BQ-exposed cells had fewer nuclei with foci) while 
exposure to ETO was intermediate to γ-radiation and CPT. 
Thus, BQ appears to cause PARP1-stabilized chicken feet 
much like CPT, suggesting a similar mechanism of action 
to this type 1 topoisomerase inhibitor.
Figure 5: Evaluation of γH2AX and 53BP1 foci in HeLa cells exposed to BQ. A. The formation of a regressed fork (chicken 
foot). The red asterix is a symbol for DNA damage that stalls a fork. This damage could be a CPT-type 1 topoisomerase cleavage 
complex. B. Representative examples of nuclei with no foci, colocalized foci, γH2AX foci, and 53BP1 foci. C. Survival fraction after 
exposure to ionizing γ-radiation [IR: 1-10 Gray (Gy)], olaparib (OLA, 10 μM), BQ, ETO and CPT. D. The percentage of nuclei with 
separated or colocalized γH2AX and 53BP1 foci. Ten or more foci are needed to be positive. The total number of nuclei observed for each 
bar and statistics are shown in supplementary tables S5 and S6, respectively.
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BQ inhibits the function of topoisomerase 1
The γH2AX and 53BP1 foci analysis supports the 
possibility that BQ directly inhibits type 1 topoisomerases. 
To test this notion, we used a standard biochemical assay 
that measures nicking and relaxing of a supercoiled 
DNA substrate. ETO (100 μM), a type 2 topoisomerase 
inhibitor, served as a negative control and did not nick 
or relax the supercoiled substrate, while CPT (500 μM) 
served as a positive control and indeed inhibited the 
relaxation of nicked circular DNA (Figure 6). Similar to 
CPT, BQ progressively inhibited the relaxing of nicked 
circular DNA from 20-70 μM and progressively inhibited 
the nicking of supercoiled DNA from 70-300 μM. Thus, 
BQ directly interferes with topoisomerase I activity.
DISCUSSION
Here we explore the nature of BQ genotoxicity 
since it is the primary metabolite suspected to cause the 
hematopoietic damage observed in people exposed to 
benzene. A non-biased approach was taken in mouse ES 
cells to identify the most critical pathways that address 
BQ-induced DNA damage. We found that DSB repair 
and replication fork maintenance pathways were essential 
for addressing these lesions. Moreover, we discovered 
that BQ interfered with type 1 topoisomerase which 
is consistent with a pathway necessary to maintain cell 
survival, replication fork stability and genome integrity.
For this proposal we performed our screen in mouse 
ES cells and comparisons to other cell types should be 
made with an understanding of their differences and 
similarities. One difference from many cells is that p53 
exhibits some, but not all, its functions. Specifically, ES 
cells do not exhibit a p53/p21-mediated G1/S checkpoint 
even though they exhibit certain hallmarks like an IR-
induced ATM/ATR response and p53-mediated increase in 
p21 transcription. In spite of these characteristics, there is 
no increase in p21 protein due to epigenetic regulation and 
proteasome-mediated degradation [49]. This is likely to 
prevent differentiation [50]. However, this p53-mediated 
response does not seem to be important for suppressing 
cancer since mice defective for it, but not other p53 
responses (p533KR/3KR) [51] and mice deleted for p53 DNA 
damage targets (p21-/-, Puma-/-, Noxa-/-) [52] do not exhibit 
early lymphomas and sarcomas as do p53-null mice [53]. 
In addition, there are intra S- and G2 checkpoints that 
are independent of p53 [54]. Moreover, human ES cells 
commit to apoptosis instead of checkpoint activation when 
exposed to DNA replication inhibitors [55] and our data 
concurs for mouse ES cells [38]. These qualities should be 
understood when using mouse ES cells in order to fairly 
compare these cells to other cell types like cancer cells and 
hematopoietic stem cells (HSCs).
There are similarities between mouse ES cells 
to cancer cells and HSCs. Like ES cells, cancer cells 
are often mutant for p53 (hence no G1/S checkpoint) 
[56] with elevated glycolysis (Warburg effect) [57–60]. 
They both are also pluripotent, immortal and oncogenic 
[61]. ES cells like stem cells exhibit self-renew and 
can be programmed to differentiate [62]. ES cells are 
also similar to HSCs with regard to the diminished 
importance of the p21 response. In mouse HSCs, p21 is 
not essential for steady-state hematopoiesis (but could 
be important under conditions of IR-induced stress) 
[63, 64]. Relevant for this project, mouse ES proliferate 
rapidly and are endowed with strong replication fork 
maintenance properties. This is important for studying 
toxins that impact HSCs since replicative stress is a major 
contributor to their functional decline and since HSCs 
accumulate DNA damage as they leave a quiescent state 
as a direct consequence of replicative stress [65, 66]. 
In addition, defects in pathways that suppress broken 
replication forks lead to a collapse of the hematopoietic 
system when challenged [67]. In concurrence with these 
observations, we find in a nonbiased screen with ES 
cells that DSB repair and replication fork maintenance 
pathways are essential to address BQ-induced damage. Of 
note, mouse ES cells mutated for excision repair genes 
display an obvious phenotype; therefore, the absence of 
phenotype for these mutant cells exposed to BQ is not due 
to naturally diminished excision repair. Thus, BQ likely 
Figure 6: BQ inhibits type 1 topoisomerase (topo 1). CPT is a positive control and ETO is a negative control. The relaxed DNA 
shown in lane 19 is a control that came with the kit.
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induces replicative stress that leads to DSBs to cause 
hematopoietic toxicity.
We propose the following model to explain 
benzene-induced hematopoietic toxicity. The benzene 
metabolite, BQ suppresses type 1 topoisomerases to 
inhibit replication fork restart and increase supercoiling 
upstream of the fork. Then PARP1-stabilized fork 
regression ameliorates the tension caused by supercoiling 
and minimizes the ATR and DNA-PKCS responses to 
phosphorylate RPA 32. An interesting observation is 
that BQ causes fewer chromosomal anomalies than 
either ETO or CPT at similarly toxic doses based on cell 
survival. It is possible that BQ is less mutagenic than 
ETO or CPT since it can inhibit type 1 topoisomerase 
nicking that would otherwise generate substrates for 
joining. Yet, imperfect repair or faulty maintenance of 
the fork would still lead to chromosomal rearrangements 
with the potential to develop into a hematopoietic 
cancer. This model proposes that people with poor 
genome maintenance capacity are at high risk for BQ-
induced disease; of particular importance is their ability 
to repair DNA DSBs and maintain stabile replication 
forks. Our results are in concordance with reports that 
describe defects in HR and FA predispose people to 
hematopoietic cancers like MDS and AML [16, 68–70]. 
These individuals would likely be more susceptible 
to BQ toxicity further increasing their risk to develop 
hematopoietic disease. Furthermore, our results 
correspond to reports that show chemotherapeutics like 
ETO cause therapy-related MDS and AML (t-MDS/
AML) [71, 72]. Benzene pollution would also have 
a greater impact on cancer patients. For such people, 
locating to a low-benzene environment would reduce 
their risk of t-MDS/AML.
MATERIALS AND METHODS
Mutant cell lines
For the experiment shown in Figure 1, we used ES 
cells mutated for NER (Xpa [73], Xpc [74]) MMR (Msh2 
[75]), error-free postreplication repair (Rad18 [76]), FA 
(Fancb [77]) and nonhomologous end joining (Ku70 [78]). 
Complete ablation of HR is cell lethal [79]; therefore, we 
use null cells for several genes that contribute to, but are 
not essential for HR (H2ax [80], Rad52 [81], Rad54 [82]). 
In addition, we have cells that are partially defective for 
essential proteins that include a deletion of Brca2 exon 
27 [26] and deletion of Brca1 exon 11 [83]. We also use 
cells defective for HR regulation that include mutations 
in the helicases Blm [84] and Recql5 [85]. We also have 
cells defective for the endonucleases Mus81 [86] and 
Ercc1 [87] and the exonuclease Trex2 [88]. All mutants 
were compared to their parental clone as we previously 
described [21].
Cell culture conditions
Mouse embryonic stem (ES) cells were cultured 
in Hyclone Dulbecco’s high glucose Modified Eagles 
Medium (GE Healthcare) with 15% fetal bovine serum 
(FBS) (Gemini bio-products), 2 mM glutamine (GIBCO), 
30 μg/mL penicillin (Sigma), 50 μg/mL streptomycin 
(GIBCO), 10-4 M β-mercaptoethanol (Sigma) and 
1000 units/mL leukemia inhibitory factor (Gemini bio-
products). Mouse ES cells were cultured on cell culture 
dishes (Corning) coated with 0.1% gelatin. HeLa cells 
were maintained in Minimal Eagle Medium (GIBCO) with 
10% FBS, 2 mM glutamine, 30 μg/mL penicillin and 50 
μg/mL streptomycin. All cell lines were grown at 37°C in 
a 5% CO2 humidified incubator.
Dose response curves
The dose response curves were performed with a 
variety of mutant cells as described [21] [22]. BQ was 
suspended in ethanol.
Two-color fluorescent in situ hybridization 
(FISH)
Mouse ES cells were cultured on 10 cm plates 
and treated with BQ, CPT, ETO or MMC at the doses 
described in figure 2. The remainder of the experiments 
were performed as described elsewhere [77].
DNA fiber assay
For the experiment shown in Figure 3A-3C, mouse 
ES cells (AB2.2 and FancbΔex2) were cultured on a 
6-well plate (Corning) and labeled with 25 μM 5-Iodo-
2’-deoxyuridine (IdU) (Sigma) at 37°C for 20 minutes. 
Labeled cells were washed twice with fresh media and 
treated 1.5 hours with either BQ (10 μM or 60 μM) or HU 
(0.5 μM). Cells were again washed twice with fresh media 
and then labeled with 250 μM 5-Chloro-2’-deoxyuridine 
(CldU) at 37°C for 20 minutes. The remainder of the 
experiment was performed as described [25]. For the 
experiment shown in Figure 3D-3F, cells were labeled 
with IdU as described above. Labeled cells were washed 
twice with fresh media and then treated for 30 minutes 
with fresh media containing 250 μM CldU plus BQ 
(10 μM or 60 μM) or ETO (1 μM) or CPT (1 μM). The 
remainder experiments were performed as previously 
described [25].
Isolation of proteins on nascent DNA (iPOND)
For the experiment shown in Figure 4, mouse ES 
cells (AB2.2) were expanded on 15 cm plates. Cells were 
incubated with 10 μM 5’-ethynyl-2’-deoxyuridine (EdU) 
(Invitrogen) for 15 minutes. Cells incorporated with EdU 
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were washed with fresh media and treated with agents BQ 
(10 μM for 1.5 hours or 60 μM for 1.5 hours), ETO (0.1 μM 
for 1.5 hours or 0.5 μM for 1.5 hours or 1 μM for 1.5 hours), 
CPT (0.1 μM for 1.5 hours or 1 μM for 1.5 hours) or HU 
(0.5 mM for 1.5 hours or 4 mM for 5 hours). The remainder 
of the experiment was performed as described [25].
Immunofluorescence (foci analysis)
For the experiment shown in Figure 5, HeLa cells 
were plated on LabTek chamber slides (Thermo scientific) 
and treated with BQ or ETO or CPT or γ-radiation (Mark1 
gamma radiation source from Shepard and Associates) 
with or without olaparib (Sellekchem) at the doses shown 
in the figure. Cells were rinsed with PBS and fixed in 2% 
formaldehyde at room temperature for 10 minutes. Cells 
were then rinsed with PBS and permeabilized with 0.5% 
Triton X-100 at room temperature for 10 minutes. After 
washing with PBS for 5 minutes, three times, cells were 
blocked in 4% non-fat milk in PBS at room temperature for 
1 hour followed by 4°C overnight incubation with a rabbit 
polyclonal antibody directed against 53BP1 (1:250) (A300-
273A, Bethyl laboratories) and mouse monoclonal antibody 
directed against γH2AX (1:250). The next morning cells 
were washed with PBS three times and incubated with 
Alexa Fluor 594-conjugated goat anti-rabbit IgG and 
Alexa Fluor 488-conjugated goat anti-mouse IgG (both 
1:1000, Molecular Probes) at RT for 1 h. After three more 
washes with PBS, cells were washed with PBS three times 
and mounted in Vectashield (Vector laboratories). Images 
were captured by Axioplan2 and analyzed by AxioVision 
software. A cell was scored as positive if it contained ≥10 
foci. More than 350 cells per each sample were counted and 
the counting assessment was done blind.
DNA cleavage assay with topoisomerase 1
DNA cleavage assays (n=3) were performed with 
the Topoisomerase I assay kit from Topogen. Reaction 
mixtures contained 1X TGS buffer (100 mM Tris (pH 
7.9), 10 mM EDTA, 1.5 M NaCl, 1% BSA, 1 mM 
spermidine, 50% glycerol) and 125 ng/μl supercoiled 
or relaxed pHOT-1 DNA. p-BQ (10-300 μM), CPT 
(100-500 μM) as a positive control or 100 μM ETO 
as a negative control and 10 U recombinant human 
topoisomerase I were added last and incubated at 37°C 
for 1 hour. Reactions were stopped by addition of 10% 
SDS. Next, 5 ng/μl proteinase K was added to detect 
clear DNA cleavages and reactions were incubated 
at 37°C for 30 minutes. Reactions were terminated 
with addition of 1X gel loading buffer (5% sarkosyl, 
0.125% bromophenol blue, 25% glycerol). Samples 
were electrophoresed onto a 1% agarose gel (Sigma) 
at 55 V for 3 hours. The gel was stained with 0.5 μg/
ml ethidium bromide (Fisher biotech) in 1X TAE buffer 
(40 mM Tris-Acetate and 1 mM EDTA (Ambion) for 30 
min. followed by a 15 min. destaining in ddH2O. DNA 
bands were captured by Gel logic 200 imaging system 
(Kodak) and Carestream MI version 5.0.7.24 software 
(Carestream Health). This assay was performed three 
times with similar results.
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